The way cancer-causing proteins accumulate in tumours may influence how effectively a promising new generation of medicines can remove them, a study suggests.

Researchers found that PROTAC (Proteolysis Targeting Chimeras) drugs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer cells continually produce in large amounts.

Influenza continues to cause major illness each year in the United States, leading to more than 35,000 deaths annually. Children, older adults, pregnant individuals, people with weakened immune systems, and those with chronic conditions such as heart disease, metabolic disorders, and cancer are especially vulnerable.

Vaccination remains the most effective way to prevent flu infection, but current vaccines do not always stop the virus from taking hold in the respiratory tract.

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.

Despite several guideline-directed medical therapies for heart failure, many patients continue to experience considerable disease burden.

A world-first clinical trial conducted by Monash University researchers has shown that cholesterol-lowering medication can reduce heart attack and stroke in people aged over 70 years.

Statins are commonly prescribed to manage high cholesterol in people up to 75 years, and are known to reduce the risk of heart attack and stroke.

Scientists from Gladstone Institutes, UC San Francisco, and Stanford University, in collaboration with Biohub, have unveiled a massive, high-resolution functional map of human immune cells that promises to transform our understanding of how genetics control health and disease.

Published in the journal Cell, the study represents a landmark achievement in immunology and genomics.

Delivering drugs directly to oral tumor sites remains challenging. A recent review involving researchers from Hasanuddin University examines barriers to local drug delivery and analyses strategies for targeting oral cancer lesions. Saliva, chewing, tongue movement, and individual tumor characteristics can affect how long a medicine remains at the treatment site and how consistently it is released.

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the University Hospital Bonn and the University of Bonn in collaboration with Prof. Robert P.